AtriCure Inc. (ATRC) Director Sells $214,400.00 in Stock
AtriCure Inc. (NASDAQ:ATRC) Director Elizabeth D. Krell sold 10,000 shares of the company’s stock in a transaction on Wednesday, May 17th. The stock was sold at an average price of $21.44, for a total transaction of $214,400.00. Following the completion of the transaction, the director now directly owns 24,162 shares of the company’s stock, valued at approximately $518,033.28. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.
AtriCure Inc. (NASDAQ:ATRC) traded up 0.33% on Monday, hitting $21.57. 38,135 shares of the company’s stock traded hands. The stock has a 50-day moving average of $20.47 and a 200-day moving average of $18.64. The stock’s market cap is $732.22 million. AtriCure Inc. has a one year low of $13.45 and a one year high of $23.95.
AtriCure (NASDAQ:ATRC) last released its earnings results on Thursday, May 4th. The medical device company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The business had revenue of $41.30 million during the quarter, compared to analysts’ expectations of $40.25 million. AtriCure had a negative net margin of 23.78% and a negative return on equity of 19.84%. The company’s quarterly revenue was up 15.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.31) earnings per share. On average, equities analysts forecast that AtriCure Inc. will post ($0.95) earnings per share for the current fiscal year.
Several research analysts recently weighed in on ATRC shares. Canaccord Genuity reaffirmed a “buy” rating and issued a $22.00 target price on shares of AtriCure in a report on Monday, April 17th. Northland Securities reaffirmed a “buy” rating and issued a $24.00 target price on shares of AtriCure in a report on Monday, March 20th. BTIG Research downgraded shares of AtriCure from a “buy” rating to a “neutral” rating in a report on Monday, March 6th. Zacks Investment Research raised shares of AtriCure from a “hold” rating to a “buy” rating and set a $26.00 target price for the company in a report on Tuesday, May 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $23.00 target price on shares of AtriCure in a report on Wednesday, March 1st. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. AtriCure presently has a consensus rating of “Buy” and a consensus target price of $22.13.
Hedge funds have recently added to or reduced their stakes in the company. Teachers Advisors LLC boosted its stake in AtriCure by 2.2% in the fourth quarter. Teachers Advisors LLC now owns 71,668 shares of the medical device company’s stock worth $1,403,000 after buying an additional 1,520 shares in the last quarter. First Light Asset Management LLC raised its position in AtriCure by 1.0% in the fourth quarter. First Light Asset Management LLC now owns 939,012 shares of the medical device company’s stock worth $18,376,000 after buying an additional 9,136 shares during the last quarter. Perceptive Advisors LLC acquired a new position in AtriCure during the fourth quarter worth $1,847,000. Tudor Investment Corp Et Al acquired a new position in AtriCure during the fourth quarter worth $253,000. Finally, Loomis Sayles & Co. L P acquired a new position in AtriCure during the fourth quarter worth $8,702,000. 79.30% of the stock is owned by institutional investors and hedge funds.
AtriCure Company Profile
AtriCure, Inc is an atrial fibrillation (Afib) solutions company. The Company develops, manufactures, and sells devices designed primarily for the surgical ablation of cardiac tissue and systems designed for the exclusion of the left atrial appendage. It has various product lines for the ablation of cardiac tissue, including its Isolator Synergy Ablation System, for the treatment of persistent and longstanding persistent forms of Afib in patients undergoing certain open concomitant procedures.
Receive News & Stock Ratings for AtriCure Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AtriCure Inc. and related stocks with our FREE daily email newsletter.